Human menstrual blood-derived stem cells reverse sorafenib resistance in hepatocellular carcinoma cells through the hyperactivation of mitophagy

Abstract Background Sorafenib is a first-line drug targeting the RTK-MAPK signalling pathway used to treat advanced hepatocellular carcinoma (HCC). However, tumour cells readily develop sorafenib resistance, limiting long-term therapy with this drug. In our previous study, we found that human menstr...

Full description

Bibliographic Details
Published in:Stem Cell Research & Therapy
Main Authors: Sining Zhou, Yiming Liu, Qi Zhang, Huikang Xu, Yangxin Fang, Xin Chen, Jiamin Fu, Yin Yuan, Yifei Li, Li Yuan, Charlie Xiang
Format: Article
Language:English
Published: BMC 2023-04-01
Subjects:
Hepatocellular carcinoma
Sorafenib resistance
MenSCs
Combination therapy
Online Access:https://doi.org/10.1186/s13287-023-03278-8

Internet

https://doi.org/10.1186/s13287-023-03278-8

Similar Items